An Indian court has ruled that Swiss pharmaceutical firm Novartis cannot obtain a new patent for a modification to an existing drug.The firm’s bid to patent a new version of anti-cancer drugs Glivec was rejected by a Chennai court because it is a new form of an existing product.
